<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Dss, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/dss-inc</link>
    <description>Latest news and press releases for Dss, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 05 Feb 2026 14:45:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/dss-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d74bc251cc36e47533410e.webp</url>
      <title>Dss, Inc.</title>
      <link>https://6ix.com/company/dss-inc</link>
    </image>
    <item>
      <title>DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering</title>
      <link>https://6ix.com/company/dss-inc/news/dss-inc-announces-closing-of-dollar10-million-underwritten-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/dss-inc/news/dss-inc-announces-closing-of-dollar10-million-underwritten-public-offering</guid>
      <pubDate>Thu, 05 Feb 2026 14:45:00 GMT</pubDate>
      <description>NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the</description>
    </item>
    <item>
      <title>DSS, Inc. Announces Pricing of $1.0 Million Underwritten Public Offering</title>
      <link>https://6ix.com/company/dss-inc/news/dss-inc-announces-pricing-of-dollar10-million-underwritten-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/dss-inc/news/dss-inc-announces-pricing-of-dollar10-million-underwritten-public-offering</guid>
      <pubDate>Wed, 04 Feb 2026 13:35:00 GMT</pubDate>
      <description>NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offe</description>
    </item>
    <item>
      <title>DSS, Inc. Announces Launch of Proposed Public Offering</title>
      <link>https://6ix.com/company/dss-inc/news/dss-inc-announces-launch-of-proposed-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/dss-inc/news/dss-inc-announces-launch-of-proposed-public-offering</guid>
      <pubDate>Wed, 04 Feb 2026 01:17:00 GMT</pubDate>
      <description>NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that it has commenced a public offering to offer and sell shares of its Common Stock. All of the shares of Common Stock are being offered by the Company (the “Offering”). The Company intends to use the net proceeds from the Offering for general corporate and working capital</description>
    </item>
    <item>
      <title>DSS, Inc.’s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger</title>
      <link>https://6ix.com/company/dss-inc/news/dss-incs-subsidiary-impact-biomedical-inc-announces-strategic-merger</link>
      <guid isPermaLink="true">https://6ix.com/company/dss-inc/news/dss-incs-subsidiary-impact-biomedical-inc-announces-strategic-merger</guid>
      <pubDate>Tue, 24 Jun 2025 12:30:00 GMT</pubDate>
      <description>NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that its subsidiary, Impact BioMedical Inc. (“Impact”), has entered into a definitive merger agreement (the “Merger Agreement”) with Dr. Ashleys Limited (“Dr. Ashleys”), a global pharmaceutical company. Under the terms of the agreement, Dr. Ashleys will acq</description>
    </item>
    <item>
      <title>DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth</title>
      <link>https://6ix.com/company/dss-inc/news/dss-inc-reports-strong-q1-2025-financial-performance-setting-the-stage-for-strategic-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/dss-inc/news/dss-inc-reports-strong-q1-2025-financial-performance-setting-the-stage-for-strategic-growth</guid>
      <pubDate>Thu, 22 May 2025 12:31:00 GMT</pubDate>
      <description>NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, today announced financial results for the first quarter of 2025, highlighting meaningful progress in its financial repositioning and a strong foundation for corporate execution in the coming quarters. In a quarter focused on streamlining operations and financial discipline, DSS delivered significant imp</description>
    </item>
  </channel>
</rss>